BACKGROUND AND OBJECTIVES: Cinacalcet, a novel calcimimetic, targets the calcium-sensing receptor to lower parathyroid hormone (PTH), calcium, and phosphorus levels in dialysis patients with secondary hyperparathyroidism (SHPT). This study compared the efficacy of a cinacalcet-based regimen with unrestricted conventional care (vitamin D and phosphate binders) for achieving the stringent National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) targets for dialysis patients. STUDY DESIGN: In this multicenter, open-label study, hemodialysis patients with poorly controlled SHPT were randomized to receive conventional care (n = 184) or a cinacalcet-based regimen (n = 368). Doses of cinacalcet, vitamin D sterols, and phosphate binders were adjusted during a 16-wk dose-optimization phase with the use of algorithms that allowed cinacalcet to be used with adjusted doses of vitamin D. The primary end point was the proportion of patients with mean intact PTH < or =300 pg/ml during a 7-wk efficacy assessment phase. RESULTS: A higher proportion of patients receiving the cinacalcet-based regimen versus conventional care achieved the targets for PTH (71% versus 22%, respectively; P < 0.001), Ca x P (77% versus 58%, respectively; P < 0.001), calcium (76% versus 33%, respectively; P < 0.001), phosphorus (63% versus 50%, respectively; P = 0.002), and PTH and Ca x P (59% versus 16%, respectively, P < 0.001), and allowed a 22% reduction in vitamin D dosage in patients receiving vitamin D at baseline. Achievement of targets was greatest in patients with less severe disease (intact PTH range, 300 to 500 pg/ml) and the cinacalcet dose required was lower in these patients (median = 30 mg/d). CONCLUSIONS: Compared with conventional therapy, a cinacalcet-based treatment algorithm increased achievement of KDOQI treatment targets in dialysis patients in whom conventional therapy was no longer effective in controlling this disease.
RCT Entities:
BACKGROUND AND OBJECTIVES:Cinacalcet, a novel calcimimetic, targets the calcium-sensing receptor to lower parathyroid hormone (PTH), calcium, and phosphorus levels in dialysis patients with secondary hyperparathyroidism (SHPT). This study compared the efficacy of a cinacalcet-based regimen with unrestricted conventional care (vitamin D and phosphate binders) for achieving the stringent National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) targets for dialysis patients. STUDY DESIGN: In this multicenter, open-label study, hemodialysis patients with poorly controlled SHPT were randomized to receive conventional care (n = 184) or a cinacalcet-based regimen (n = 368). Doses of cinacalcet, vitamin D sterols, and phosphate binders were adjusted during a 16-wk dose-optimization phase with the use of algorithms that allowed cinacalcet to be used with adjusted doses of vitamin D. The primary end point was the proportion of patients with mean intact PTH < or =300 pg/ml during a 7-wk efficacy assessment phase. RESULTS: A higher proportion of patients receiving the cinacalcet-based regimen versus conventional care achieved the targets for PTH (71% versus 22%, respectively; P < 0.001), Ca x P (77% versus 58%, respectively; P < 0.001), calcium (76% versus 33%, respectively; P < 0.001), phosphorus (63% versus 50%, respectively; P = 0.002), and PTH and Ca x P (59% versus 16%, respectively, P < 0.001), and allowed a 22% reduction in vitamin D dosage in patients receiving vitamin D at baseline. Achievement of targets was greatest in patients with less severe disease (intact PTH range, 300 to 500 pg/ml) and the cinacalcet dose required was lower in these patients (median = 30 mg/d). CONCLUSIONS: Compared with conventional therapy, a cinacalcet-based treatment algorithm increased achievement of KDOQI treatment targets in dialysis patients in whom conventional therapy was no longer effective in controlling this disease.
Authors: William G Goodman; Gerald A Hladik; Stewart A Turner; Peter W Blaisdell; David A Goodkin; Wei Liu; Yousri M Barri; Raphael M Cohen; Jack W Coburn Journal: J Am Soc Nephrol Date: 2002-04 Impact factor: 10.121
Authors: J-C Souberbielle; A Boutten; M-C Carlier; D Chevenne; G Coumaros; E Lawson-Body; C Massart; M Monge; J Myara; X Parent; E Plouvier; P Houillier Journal: Kidney Int Date: 2006-06-21 Impact factor: 10.612
Authors: Jill S Lindberg; Bruce Culleton; Gordon Wong; Michael F Borah; Roderick V Clark; Warren B Shapiro; Simon D Roger; Fred E Husserl; Preston S Klassen; Matthew D Guo; Moetaz B Albizem; Jack W Coburn Journal: J Am Soc Nephrol Date: 2005-02-02 Impact factor: 10.121
Authors: Sharon M Moe; Glenn M Chertow; Jack W Coburn; L Darryl Quarles; William G Goodman; Geoffrey A Block; Tilman B Drüeke; John Cunningham; Donald J Sherrard; Laura C McCary; Kurt A Olson; Stewart A Turner; Kevin J Martin Journal: Kidney Int Date: 2005-02 Impact factor: 10.612
Authors: Kevin J Martin; Harald Jüppner; Donald J Sherrard; William G Goodman; Mark R Kaplan; George Nassar; Patricia Campbell; Mario Curzi; Chaim Charytan; Laura C McCary; Matthew D Guo; Stewart A Turner; David A Bushinsky Journal: Kidney Int Date: 2005-09 Impact factor: 10.612
Authors: José Portolés; Paula López-Sánchez; María Auxiliadora Bajo; Inés Castellano; Gloria del Peso; José Ramón Rodríguez; Mayte Ribera; Almudena Ortigosa; Rafael Selgas Journal: Perit Dial Int Date: 2012 Mar-Apr Impact factor: 1.756
Authors: David M Spiegel; Lesley McPhatter; Ann Allison; Joanne C Drumheller; Robert Lockridge Journal: Clin J Am Soc Nephrol Date: 2012-02-02 Impact factor: 8.237
Authors: Stuart M Sprague; James B Wetmore; Konstantin Gurevich; Gerald Da Roza; John Buerkert; Maureen Reiner; William Goodman; Kerry Cooper Journal: Clin J Am Soc Nephrol Date: 2015-04-14 Impact factor: 8.237
Authors: James B Wetmore; Konstantin Gurevich; Stuart Sprague; Gerald Da Roza; John Buerkert; Maureen Reiner; William Goodman; Kerry Cooper Journal: Clin J Am Soc Nephrol Date: 2015-04-22 Impact factor: 8.237
Authors: James B Wetmore; Shiguang Liu; Ron Krebill; Rochelle Menard; L Darryl Quarles Journal: Clin J Am Soc Nephrol Date: 2009-11-05 Impact factor: 8.237